

therapeutically effective amount of a lymphotoxin-beta receptor (LT- [theta]  $\beta$ -R) blocking agent.

3. (Amended) The method of claim 2 wherein the composition is selected from the group consisting of a soluble LT- $\beta$  [theta] receptor, [anti-LT - $\alpha$  antibodies, anti -LT-[theta]-antibodies], and anti-LT- $\beta$  [theta]-R antibodies.

7. (Amended) The method according to claim 4 wherein the soluble lymphotoxin- $\beta$  [theta] receptor comprises a ligand binding domain that can selectively bind to a surface LT ligand.

8. (Amended) The method according to claim 7 wherein the LT- $\beta$  [theta]-receptor comprises a human immunoglobulin FC domain.

9. (Amended) The method according to claim 3 wherein the composition comprises a monoclonal antibody directed against an LT- $\beta$  [theta] receptor.

11. (Amended) A composition for the treatment of a subject having follicular lymphoma which blocks the interaction of LT- $\beta$  [theta] with its receptor.

18. (Amended) A method for altering the survival or maintenance of follicular dendritic cells in a subject comprising administering an inhibitor of the interaction between LT- $\beta$  [ $\beta$ ] and its receptor.

19. (Amended) A method for altering the architecture of the organs of the immune system by administering (a) an inhibitor of the interaction between LT- $\beta$  [ $\beta$ ] and its receptor; and (b) an inhibitor of the signaling pathway of an additional member of the TNF family of ligands and receptors.

#### **REMARKS**

Applicants are submitting herewith a SUBSTITUTE specification excluding claims in accordance with 37 C.F.R. 1.125. Upon review of the application Applicants